

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE THIRD QUARTER ENDED 30 APRIL 2025<sup>(1)</sup>**

	<b>INDIVIDUAL QUARTER</b>		<b>CUMULATIVE QUARTER</b>	
	<b>30.4.2025</b>	<b>30.4.2024</b>	<b>30.4.2025</b>	<b>30.4.2024</b>
	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
Revenue	11,640	11,690	36,274	39,694
Cost of sales	(6,719)	(6,503)	(21,074)	(23,176)
Gross profit	4,921	5,187	15,200	16,518
Other income	386	329	1,139	1,178
Marketing expenses	(242)	(237)	(907)	(758)
Administrative and other expenses	(2,638)	(2,981)	(8,067)	(7,988)
Finance costs	(15)	(26)	(59)	(105)
Profit before tax	2,412	2,272	7,306	8,845
Taxation	(477)	(676)	(1,551)	(2,586)
Profit for the financial period	1,935	1,596	5,755	6,259
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	1,935	1,596	5,755	6,259
Profit attributable to:				
Owners of the parent	1,904	1,583	5,640	5,952
Non-controlling interests	31	13	115	307
	1,935	1,596	5,755	6,259
Earnings per share attributable to owners of the parent ("EPS"):				
Basic and diluted <sup>(2)</sup> (sen)	0.51	0.42	1.51	1.59

**Notes:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 APRIL 2025<sup>(1)</sup>**

	Unaudited as at 30 April 2025 RM'000	Audited as at 31 July 2024 RM'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	31,566	28,303
Right-of-use assets	4,659	4,689
Deferred tax assets	1	-
Goodwill	287	287
<b>Current assets</b>		
Inventories	16,580	14,569
Trade and other receivables	16,318	20,131
Marketable securities	6,396	9,278
Current tax assets	2,120	1,219
Derivative assets	-	-
Cash and bank balances	9,685	4,232
<b>TOTAL ASSETS</b>	<b>87,612</b>	<b>82,708</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	44,348	44,348
Reserves	33,277	27,636
Equity attributable to owners of the parent	<b>77,625</b>	<b>71,984</b>
Non-controlling interest	1,068	789
<b>TOTAL EQUITY</b>	<b>78,693</b>	<b>72,773</b>
<b>Non-current liabilities</b>		
Borrowings	127	256
Lease liabilities	38	-
Government grants	2,503	2,503
Deferred tax liabilities	1,465	1,151
<b>Current liabilities</b>		
Trade and other payables	4,341	4,445
Borrowings	216	606
Lease liabilities	10	14
Government grants	219	430
Current tax liabilities	-	530
<b>TOTAL LIABILITIES</b>	<b>8,919</b>	<b>9,935</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>87,612</b>	<b>82,708</b>

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 APRIL 2025<sup>(1)</sup> (cont'd)**

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE THIRD QUARTER ENDED 30 APRIL 2025<sup>(1)</sup>**

	Attributable to owners of the Parent					
	Non-distributable		Distributable		Non-controlling interest	Total equity
	Share capital	Reorganisati on debit reserve	Retained earnings	Total		
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 August 2024	44,348	(6,851)	34,488	71,985	788	72,773
Profit for the financial period	-	-	5,640	5,640	115	5,755
Other comprehensive income, net of tax	-	-	-	-	-	-
Total comprehensive income	-	-	5,640	5,640	115	5,755
<u>Transactions with owners</u>						
- Dividend paid	-	-	-	-	(60)	(60)
- Ordinary shares	-	-	-	-	225	225
Total transaction with owners	-	-	-	-	165	165
<b>Balance as at 30 April 2025</b>	<b>44,348</b>	<b>(6,851)</b>	<b>40,128</b>	<b>77,625</b>	<b>1,068</b>	<b>78,693</b>

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE THIRD QUARTER ENDED 30 APRIL 2025<sup>(1)</sup>**

	9-month ended 30 April 2025 RM'000	9-month ended 30 April 2024 RM'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before tax	7,306	8,845
Adjustments for:		
Depreciation of property, plant and equipment	2,050	1,755
Depreciation of right-of-use assets	91	99
Amortisation of government grants	(277)	(278)
Finance costs	59	105
Interest income	(226)	(150)
Distribution income from short-term fund	(168)	(276)
Property, plant and equipment written off	-	4
Realised gain on fair value adjustment on marketable securities	-	-
Unrealised loss/(gain) on foreign exchange	82	(103)
Fair value loss on derivative asset	-	6
Operating profit before changes in working capital	8,917	10,007
Increase in inventories	(2,011)	(2,003)
Decrease/(increase) in trade and other receivables	3,813	(6,440)
(Decrease)/increase in trade and other payables	(118)	1,494
Cash generated from operations	10,601	3,058
Government grants received	66	-
Interest received	226	150
Tax paid	(2,671)	(1,785)
Tax refunded	2	169
<b>Net cash from operating activities</b>	<b>8,224</b>	<b>1,592</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of marketable securities	(4,500)	(5,150)
Purchase of property, plant and equipment	(5,313)	(1,783)
Proceeds from disposal of marketable securities	7,550	5,250
<b>Net cash used in investing activities</b>	<b>(2,263)</b>	<b>(1,683)</b>

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD QUARTER ENDED 30 APRIL 2025<sup>(1)</sup> (Cont'd)**

	9-month ended 30 April 2025 RM'000	9-month ended 30 April 2024 RM'000
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Capital contribution of non-controlling interest	225	-
Dividend paid to non-controlling interest	(60)	-
Drawdown of bankers' acceptance	-	-
Repayment of bankers' acceptance	-	-
Repayment of term loans	(519)	(2,545)
Interest paid	(58)	(104)
Payment of lease liabilities	(28)	(38)
<b>Net cash used in financing activities</b>	<b>(440)</b>	<b>(2,687)</b>
Net increase/(decrease) in cash and cash equivalents	5,521	(2,778)
Effect of foreign exchange rates changes	(68)	107
Cash and cash equivalents at beginning of financial year	4,232	6,107
Cash and cash equivalents at end of financial period	9,685	3,436

**Notes:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

## **A. NOTES TO THE INTERIM FINANCIAL REPORT**

### **A1. Basis of preparation**

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad (“Listing Requirements”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

### **A2. Significant Accounting Policies**

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2024, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

#### **(a) New MFRSs adopted during the financial period**

The Group and the Company adopted the following Standards and Amendments to Standards of the MFRS Framework that were issued by the MASB during the financial periods:

<b>Title</b>	<b>Effective Date</b>
MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Initial Application of MFRS 17 and MFRS 9 - Comparative Information</i>	1 January 2023
Amendments to MFRS 101 <i>Disclosure of Accounting Policies</i>	1 January 2023
Amendments to MFRS 108 <i>Definition of Accounting Estimates</i>	1 January 2023
Amendments to MFRS 112 <i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>	1 January 2023
Amendments to MFRS 112 <i>International Tax Reform - Pillar Two Model Rules</i>	Refer paragraph 98M of MFRS112

Adoption of the above Standards and Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company.

#### **(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2024**

The following are Standards and Amendments to Standards of the MFRS Framework that have been issued by the MASB but have not been early adopted by the Group and the Company:

<b>Title</b>	<b>Effective Date</b>
Amendment to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 <i>Statement of Cash Flows</i> and MFRS 7 <i>Financial Instruments: Disclosure – Supplier Finance Arrangement</i>	1 January 2024
Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 9 and MFRS 7 <i>Classification and Measurement of Financial Instruments</i>	1 January 2026
Amendments to <i>Annual Improvements to MFRS Accounting Standards – Volume 11</i>	1 January 2026
MFRS 18 <i>Presentation and Disclosure in Financial Statements</i>	1 January 2027
MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i>	1 January 2027
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

**A3. Auditors' Report**

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2024.

**A4. Seasonal or Cyclical Factors**

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial period under review.

**A5. Material Unusual Items**

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period under review.

**A6. Material Changes in Estimates**

There were no changes in estimates that have a material effect in the current quarter and financial period under review.

**A7. Debt and Equity Securities**

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial period under review.

**A8. Dividend Paid**

No dividend was paid during the current quarter.

**A9. Segmental Information**

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

- (a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and
- (b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial period under review is as follows:

<b>30 April 2025</b>	<b>Manufacturing</b>	<b>Marketing and distribution</b>	<b>Eliminations</b>	<b>Consolidated</b>
	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
<b>Results</b>				
Revenue from external customers	11,486	24,788	-	36,274
Inter-segment revenue	2,488	217	(2,705)	-
Total revenue	13,974	25,005	(2,705)	36,274
Interest income and distribution income from short-term fund	151	243	-	394
Interest expense	(15)	(53)	9	(59)
Net Interest income	136	190	9	335
Segment profit before tax	3,061	4,468	(223)	7,306



**A10. Material Events Subsequent to the end of the Quarter**

There were no other material events subsequent to the end of the current quarter and financial year under review that have not been reflected in this interim financial report.

**A11. Changes in the Composition of the Group**

On 10 October 2024, UMC subscribed an additional 675,000 new ordinary shares in Ateria Medika Sdn. Bhd. ("Ateria") at an issue price of RM1.00 per share, for a cash consideration of RM675,000 ("Subscription").

Upon completion of the Subscription, Ateria is now a 90%-owned subsidiary of UMC.

On 18 December 2024, UMC subscribed an additional 349,930 new ordinary shares in Akiteck (Malaysia) Sdn. Bhd. ("Akiteck") at an issue price of RM1.00 per share, for a cash consideration of RM349,930 ("Subscription").

Upon completion of the Subscription, Akiteck is now a 70%-owned subsidiary of UMC.

On 11 March 2025, UMC had incorporated a 85% owned new subsidiary known as Rescue Medik Sdn. Bhd. ("Rescue Medik") with paid-up share capital of RM1,000 comprising 1,000 ordinary shares. The intended principal activities of Rescue Medik are marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services.

Apart from the above, there were no changes in the composition of the Group during the current quarter and financial year under review.

**A12. Contingent Liabilities and Contingent Assets**

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

**A13. Material Capital Commitment**

Save as disclosed below, as at 30 April 2025, the Group does not have any other material capital commitment:

	RM'000
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	6,884
- Approved but not contracted for	6,800
<b>Total</b>	<b>13,684</b>

**A14. Significant Related Party Transactions**

There were no significant related party transactions during the current quarter.

**A15. Derivative Financial Instruments**

As at 30 April 2025, the Group does not have any derivatives financial instruments.

**A16. Fair Value of Financial Liabilities**

There were no gains or losses arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

## **B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS**

### **B1. Review of Performance**

	Individual Quarter 3-months ended		Cumulative Quarter 9-months ended	
	30 April 2025 (RM'000)	30 April 2024 (RM'000)	30 April 2025 (RM'000)	30 April 2024 (RM'000)
Revenue	11,640	11,690	36,274	39,694
Profit before tax ("PBT")	2,412	2,272	7,306	8,845
Profit for the financial period	1,935	1,596	5,755	6,259
Profit attributable to owners of the parent	1,904	1,583	5,640	5,952

The Group's revenue decreased by approximately RM0.05 million or 0.43% from approximately RM11.69 million achieved in the corresponding quarter of the previous financial year to approximately RM11.64 million in the current quarter.

The PBT of the Group increased by approximately RM0.14 million or 6.16% from approximately RM2.27 million in the corresponding quarter of the previous financial year to approximately RM2.41 million in the current quarter.

The decrease in revenue in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The marginal decrease was mainly due to unfavourable foreign currency exchange for manufacturing segment.

### **B2. Comparison with Immediate Preceding Quarter**

	Individual Quarter 3-months ended			
	30 April 2025 (RM'000)	31 January 2025 (RM'000)	Differences	
			RM'000	%
Revenue	11,640	11,579	61	0.53
PBT	2,412	2,463	(51)	(2.07)
Profit for the financial period	1,935	1,995	(60)	(3.01)
Profit attributable to owners of the parent	1,904	1,891	13	0.69

The Group's revenue increased by approximately RM0.06 million or 0.53% from approximately RM11.58 million achieved in the immediate preceding quarter to approximately RM11.64 million in the current quarter. The increase in revenue was mainly derived from the increase orders from manufacturing segment.

The Group's PBT decreased by approximately RM0.05 million or 2.07% from approximately RM2.46 million achieved in the immediate preceding quarter to approximately RM2.41 million in the current quarter.

### **B3. Prospects**

Given the Malaysian government's sustained commitment towards advancing the nation's healthcare standards, UMC remains optimistic about its future growth trajectory driven by key factors such as the increasing demand for healthcare facility upgrades, healthcare tourism as well as the immense need to address facility overcrowding, enabling the Group to further solidify its pivotal role within the ever-evolving healthcare landscape.

Aligned with that, the government allocated RM45.3 billion to Ministry of Health under Budget 2025 which represented a 10.0% increase over the preceding year's RM41.2 billion. This makes it the second largest budget allocation which is a testament of the government's resolute emphasis in delivering quality healthcare, underscoring the growing importance of both the public and private healthcare sectors. Additionally, RM1.35 billion has been earmarked for the upgrading and repairing of healthcare facilities, fostering a supportive environment for growth within Malaysia's healthcare sector which bodes well with the Group's financial outlook over the coming periods.

### B3. Prospects (Cont'd)

Building upon its established presence within the medical device sector, UMC has strategically undertaken a series of key initiatives to further elevate its market position within the broader healthcare industry. These strategic developments encompass the incorporation of new subsidiary entities known as Akiteck and Ateria to venture into medical moulding solutions as well as the import and export of medical devices. To broaden its horizons, the Group has extended its reach into healthcare services through Rescue Medic Sdn Bhd which encompasses the provision of ambulance vehicles and essential equipment, a purpose-built care centres, as well as the operation of its own dedicated ambulance services. Concurrently, within its manufacturing division, UMC is actively undertaking its next expansionary phase through the integration of advanced manufacturing technologies and expansion of its clean room facility to cater to the growing demand globally.

Given the several strategic initiatives undertaken by the Group, it believes that it is well poised for growth and aims to meet the anticipated growing demand to further enhance its overall presence within the medical industry.

### B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

### B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 30 April 2025 RM'000	3-month ended 30 April 2024 RM'000	9-month ended 30 April 2025 RM'000	9-month ended 30 April 2024 RM'000
<b>Income tax</b>				
Current tax expenses based on profit for the financial period	279	498	1,310	1,793
(Over)/under provision of tax expense in prior year	(72)	26	(72)	47
<b>Deferred tax</b>				
Relating to origination and reversal of temporary differences	270	152	313	746
Under/(over)provision in prior years	-	-	-	-
Overall tax expenses	477	676	1,551	2,586
Effective tax rate (%)	19.78	29.75	21.23	29.24
Statutory tax rate (%)	24.00	24.00	24.00	24.00

The Group's effective tax rate was at 21.23% for current financial period. The effective tax rate for current financial period was lower than the statutory tax rate of 24.00% mainly due to:

- (i) tax incentive enjoyed by its wholly-owned subsidiary, UWHM Sdn Bhd. UWHM Sdn Bhd is entitled to reinvestment allowance incentives under Schedule 7A, Income Tax Act 1967 for qualifying capital expenditure on the acquisition of machinery and equipment and;
- (ii) amortisation of grants, which was not subject to income tax.

**B6. Status of Corporate Proposals**

There were no corporate proposals announced and not completed as at the date of this interim financial report.

**B7. Utilisation of Proceeds from the IPO**

The gross proceeds from the IPO amounting to RM31.11 million is expected to be utilised in the following manner:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon listing <sup>(1)</sup>	Proposed Utilisation RM'000	Actual Utilisation RM'000	Percentage utilised %	Deviation	
					RM'000	%
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months	3,500	3,500 <sup>(2)</sup>	100.00	-	-
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months	6,800	-	-	-	-
		10,300	3,500	33.98	-	-
Repayment of bank borrowings <sup>(3)</sup>	Within six (6) months	9,000	9,000	100.00	-	-
Working capital	Within thirty-six (36) months	8,662	8,662	100.00	-	-
Estimated listing expenses	Within two (2) months	3,150	3,150	100.00	-	-
<b>Total</b>		<b>31,112</b>	<b>24,312</b>			

**Notes:**

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) As stated in Section 3.7.1(i) of the Prospectus, the excess amount of approximately RM0.17 million has been used for working capital purposes.
- (3) Including lease liabilities owing to financial institutions.

(The remaining of this page is intentionally left blank)

## B8. Group Borrowings and Debt Securities

The details of the Group's borrowings are as follows:

	9-month ended 30 April 2025 RM'000	Audited as at 31 July 2024 RM'000
<b>Current liabilities</b>		
Term loan	216	606
Bankers' acceptance	-	-
	<b>216</b>	<b>606</b>
<b>Non-current liabilities</b>		
Term loan	127	256
	<b>127</b>	<b>256</b>
<b>Total borrowings</b>	<b>343</b>	<b>862</b>

All the Group's borrowings are denominated in RM, secured and interest-bearing.

## B9. Material Litigation

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

## B10. Dividend

No dividend has been declared or recommended for the current quarter ended 30 April 2025.

## B11. Earnings Per Share

The basic and diluted EPS for the current quarter and financial period are computed as follows:

	3-month ended 30 April 2025	3-month ended 30 April 2024	9-month ended 30 April 2025	9-month ended 30 April 2024
Profit attributable to the owners of the parent (RM'000)	1,904	1,583	5,640	5,952
Number of ordinary shares (unit) ('000)	373,910	373,910	373,910	373,910
Basic EPS <sup>(1)</sup> (sen)	0.51	0.42	1.51	1.59
Diluted EPS <sup>(2)</sup> (sen)	0.51	0.42	1.51	1.59

### Notes:

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**B.12 Profit Before Tax**

Profit before tax is arrived at after charging/(crediting):

	<b>9-month ended 30 April 2025</b>	<b>9-month ended 30 April 2024</b>
	<b>RM'000</b>	<b>RM'000</b>
Depreciation of property, plant and equipment	2,050	1,755
Depreciation of right-of-use assets	91	99
Amortisation of government grants	(277)	(278)
Finance costs	59	105
Interest income	(226)	(150)
Distribution income from short-term fund	(168)	(276)
Property, plant and equipment written off	-	4
Realised gain on fair value adjustment on marketable securities	-	-
Unrealised gain on foreign exchange	(82)	(103)
Fair value loss on derivative asset	-	6

**Notes:**

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

**BY ORDER OF THE BOARD**  
**5 June 2025**